Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25609417 | 0.90 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL17282166 | 0.88 | MAPT (0.50) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL28490097 | 0.86 | MAPT (0.42) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL13734508 | 0.84 | MAPT (0.47) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL27629749 | 0.84 | MAPT (0.57) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL24954636 | 0.81 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL27987960 | 0.81 | MAPT (0.54) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL19967010 | 0.81 | MAPT (0.49) | MAPTALDH1A1MEN1KMT2ATSHR | |
| SCHEMBL8259396 | 0.80 | ALDH1A1 (0.56) | ALDH1A1TSHRHTTCYP2C19KDM4E | |
| SCHEMBL16701742 | 0.80 | GAA (0.42) | MAPTALDH1A1MEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | ASIERIS PHARMACEUTICALS (SHANGHAI) CO., LTD. (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-05-11 | — | — | US | disclosed |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-19 | — | — | US | disclosed |
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | UNIVERSITY OF WOLLONGONG (AU) | 2016-01-14 | — | — | US | disclosed |
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| US-7569604-B2 | Heterocyclic derivatives for modulation of calcium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-04 | — | — | US | disclosed |
| US-7326790-B2 | Diphenylisoxazole compounds and hydro isomers thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2008-02-05 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7247641-B2 | Compounds, derivatives, compositions, preparation and uses | MGI GP, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7220745-B2 | Heterocyclic compounds useful to treat HCV | RIGEL PHARMACEUTICALS (US) | 2007-05-22 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | MAPT 3241/4885ALDH1A1 503/4885MEN1 4369/4885 |
| US-20090253682-A1 | HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS | CACNA1D, ORAI1, CACNA1C | MAPT 1243/4885ALDH1A1 3826/4885MEN1 3121/4885 |
| US-20230146675-A1 | PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD5, ENTPD1, SLC29A1 | MAPT 4694/4885ALDH1A1 226/4885MEN1 2618/4885 |
| US-10208021-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | TFPI, TFPI2, KLKB1 | MAPT 4337/4885ALDH1A1 3227/4885MEN1 367/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | MAPT 2827/4885ALDH1A1 1683/4885MEN1 4394/4885 |
| US-20180201603-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | MAPT 4337/4885ALDH1A1 3227/4885MEN1 367/4885 |
| US-20160009733-A1 | REGULATION OF NITRIC OXIDE RELEASE AND BIOFILM DEVELOPMENT | NOS1, NOS2, NOS3 | MAPT 4465/4885ALDH1A1 2257/4885MEN1 3926/4885 |
| US-20230295094-A1 | NITROXOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOS1, NQO1, NOS2 | MAPT 3319/4885ALDH1A1 752/4885MEN1 569/4885 |
| US-20160024080-A1 | NEW COMPOUNDS | QSOX1, MAOB, MAOA | MAPT 4113/4885ALDH1A1 120/4885MEN1 2307/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | MAPT 3003/4885ALDH1A1 1926/4885MEN1 4519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.